Impact of Delay to Angioplasty in Patients With Acute Coronary Syndromes Undergoing Invasive Management Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial by Sorajja, Paul et al.
T
l
h
F
a
C
l
M
O
C
Y
B
i
S
S
a
Journal of the American College of Cardiology Vol. 55, No. 14, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00
PCLINICAL RESEARCH Invasive and Interventional Cardiology
Impact of Delay to Angioplasty
in Patients With Acute Coronary Syndromes
Undergoing Invasive Management
Analysis From the ACUITY (Acute Catheterization
and Urgent Intervention Triage strategY) Trial
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Objectives The aim of this study was to determine the impact of delay to angioplasty in patients with acute coronary
syndromes (ACS).
Background There is a paucity of data on the impact of delays to percutaneous coronary intervention (PCI) in patients with
non–ST-segment elevation acute coronary syndromes (NSTE-ACS) undergoing an invasive management strategy.
Methods Patients undergoing PCI in the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial were
stratified according to timing of PCI after clinical presentation for outcome analysis.
Results Percutaneous coronary intervention was performed in 7,749 patients (median age 63 years; 73% male) with
NSTE-ACS at a median of 19.5 h after presentation (8 h [n  2,197], 8 to 24 h [n  2,740], and 24 h [n 
2,812]). Delay to PCI 24 h after clinical presentation was significantly associated with increased 30-day mortality,
myocardial infarction (MI), and composite ischemia (death, MI, and unplanned revascularization). By multivariable
analysis, delay to PCI of 24 h was a significant independent predictor of 30-day and 1-year mortality. The incremen-
tal risk of death attributable to PCI delay 24 h was greatest in those patients presenting with high-risk features.
Conclusions In this large-scale study, delaying revascularization with PCI 24 h in patients with NSTE-ACS was an indepen-
dent predictor of early and late mortality and adverse ischemic outcomes. These findings suggest that urgent
angiography and triage to revascularization should be a priority in NSTE-ACS patients. (J Am Coll Cardiol 2010;
55:1416–24) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.063c
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ccepted November 9, 2009.oronary syndromes (NSTE-ACS) (1–5). Randomized
linical trials have demonstrated that the benefits of an early
nvasive strategy in these patients occur early, persist in
ong-term follow-up, and are particularly evident in high-
isk patients. These observations have led to the adoption of
n early invasive strategy in the management of many
atients with NSTE-ACS, with angiography typically per-
ormed within 48 to 72 h of hospital admission (6,7).
See page 1425
Nonetheless, within the framework of an early invasive
trategy, there is a paucity of data on precisely when
ngiography and revascularization should take place in
atients with NSTE-ACS (8–12). Expeditious angiogra-
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April 6, 2010:1416–24 Risk of PCI Delay in ACShy and revascularization might hasten definitive manage-
ent, reduce the need for prolonged antithrombotic therapy
nd its potential associated complications (i.e., bleeding),
nd lead to shortened hospital stay. One modest-sized
andomized trial of immediate versus delayed cardiac catheter-
zation in patients with NSTE-ACS found a significant
eduction in death and myocardial infarction (MI) among
atients who underwent angiography 6 h after hospital
dmission versus several days later (13). A second, larger
andomized trial found no benefit of early intervention for
STE-ACS, except in those patients who were at high risk
14). Some studies have reported fewer complications
hen revascularization with percutaneous coronary inter-
ention (PCI) is performed after several days of medical
tabilization (11). Because the implications for patient
anagement and the timing of triage are potentially
ubstantial, further data are needed on the relationship
etween clinical presentation and time to revasculariza-
ion in patients with NSTE-ACS.
Accordingly, with data from the large-scale, prospec-
ive, controlled ACUITY (Acute Catheterization and
rgent Intervention Triage strategY) trial, we sought to
xamine the appropriate timing of revascularization with
CI after clinical presentation in patients with NSTE-ACS.
ethods
tudy population. The details of the ACUITY trial pro-
ocol have been previously published (15,16). Briefly, the
CUITY trial was a prospective, open-label, randomized,
ulticenter trial in which patients with NSTE-ACS under-
oing an early invasive management strategy were randomized
o receive 1 of 3 antithrombotic regimens: 1) unfractionated or
ow molecular weight heparin plus a glycoprotein IIb/IIIa
nhibitor; 2) bivalirudin plus a glycoprotein IIb/IIIa inhibitor;
r 3) bivalirudin alone. Patients were eligible for study
articipation if they were 18 years of age with symptoms
f NSTE-ACS within the preceding 24 h and if 1 or more
f the following criteria were met: new ST-segment depres-
ion or transient elevation of 1 mm; elevations in the
roponin I, troponin T, or creatine kinase-MB levels;
nown coronary artery disease; or all 4 other variables for
redicting Thrombolysis In Myocardial Infarction (TIMI)
isk scores for unstable angina (17). Exclusion criteria were
T-segment elevation MI or cardiogenic shock; bleeding
iathesis or major bleeding episode within 2 weeks; throm-
ocytopenia; a calculated creatinine clearance rate of 30
l/min; recent administration of abciximab, warfarin,
ondaparinux, fibrinolytic agents, bivalirudin, or 2 or more
oses of low-molecular-weight heparin; and allergy to any
f the study drugs or to iodinated contrast medium that
ould not be controlled in advance with medication.
Patients who were randomized to a glycoprotein IIb/IIIa
eceptor inhibitor were randomized further to receive the
rug immediately after randomization (i.e., upstream) or
nly at the time of PCI. Angiography was performed within t2 h in all patients. Of the 13,819
atients enrolled in the ACUITY
rial, 7,789 patients (56%) under-
ent PCI at the discretion of the
ocal physician after diagnostic an-
iography. The timing of angiog-
aphy was known in 7,749 of these
atients who comprise the study
ohort examined in the present
nvestigation.
efinitions and end points.
linical follow-up was performed
t 1 month and 12 months. As
reviously described, 3 primary
nd points at 30 days were prespecified: composite ischemia
death from any cause, MI, or unplanned revascularization
or ischemia), major bleeding (not related to coronary artery
ypass grafting [CABG]), and net adverse clinical events
composite ischemia or major bleeding) (15,16). Major
leeding was defined as intracranial or intraocular bleed-
ng, hemorrhage at the access site requiring intervention,
ematoma with a diameter of 5 cm, a reduction in
emoglobin levels of 4 g/dl without an overt bleeding
ource or 3 g with such a source, reoperation for
leeding, or transfusion of a blood product (15,16). A
linical events committee that was blinded to treatment
ssignment adjudicated all study end points (15,16).
ata analysis. Patients were stratified by time from hos-
ital presentation to revascularization with PCI into 3
pproximately equal-size groups: 8 h, 8 to 24 h, and 24
. To analyze the acute risk of the patient as a potential
onfounder, the TIMI risk score for NSTE-ACS was
alculated for each patient (0 to 2  low-risk; 3 to 4 
ntermediate-risk; 5 to 7  high-risk) (17). Cox propor-
ional hazards models were constructed to determine the
ndependent correlates of adverse event outcomes with the
ollowing nominal candidate variables: age 75 years, male
ex, diabetes mellitus, current smoker, hypertension, abnor-
al cardiac biomarkers, ST-segment deviation 1 mm,
rior transient ischemic attack or stroke, anemia (baseline
emoglobin 12 g/dl or hematocrit 36% for women and
emoglobin 13 g/dl or hematocrit 39% for men),
reatinine clearance 60 ml/min, multivessel coronary dis-
ase, recent medication use before admission (aspirin, beta-
lockers, statins, prior antithrombin use, angiotensin-
onverting enzyme inhibitors or angiotensin receptor
lockers, thienopyridines), and time duration 24 h from
ospital admission to PCI. Event rates were determined and
isplayed with the Kaplan-Meier method with comparisons
erformed with the log-rank test. Categorical variables were
ompared with the Fisher exact test for pairwise compari-
ons and the chi-square test for trend for multiple compar-
sons. Continuous variables are expressed as medians with
nterquartile ranges in parentheses and were compared with
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
MI  myocardial infarction
NSTE-ACS  non–ST-
segment elevation acute
coronary syndrome
PCI  percutaneous
coronary intervention
TIMI  Thrombolysis In
Myocardial Infarctionhe nonparametric Kruskal-Wallis test.
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aseline characteristics. Tables 1 and 2 list the baseline,
linical, and angiographic characteristics of the overall study
ohort, stratified according to time from hospital presenta-
ion to revascularization with PCI. Median time to PCI was
9.5 h in all patients and 3.5 h, 18.1 h, and 39.2 h in those
ndergoing PCI in8 h, 8 to 24 h, and24 h, respectively,
fter hospital presentation. Patients who underwent PCI
24 h after hospital presentation more frequently had
levation of cardiac troponins, high TIMI risk score (5 to 7),
eft main culprit lesion, baseline TIMI flow grade 3, prior
istory of diabetes mellitus, MI, left main disease, CABG,
nd prior use of antithrombins and thienopyridines. Pa-
ients with delay to PCI also had a lower incidence of home
spirin and beta-blocker use compared with patients who
nderwent earlier PCI. There was no difference in proce-
ural success and final TIMI flow after PCI for the 3 patient
roups.
0-day and 1-year clinical outcomes. Clinical follow-up
as available in 7,627 patients (98%) at 30 days. There were
o significant differences in the 30-day or 1-year rates of
eath or the combined end point of death or MI in patients
ho underwent PCI 8 h versus those who had PCI 8 to
Baseline Characteristics According to Time to PTable 1 Baseline Characteristics According
<8 h
Age, yrs, median (range) 63 (25–92)
Male sex (%) 73.6
U.S. patients (%) 51.4
Weight, kg, median (IQR) 84 (75–95)
Medical history (%)
Diabetes mellitus 26.1
Insulin-requiring 8.6
Current smoker 30.2
Hyperlipidemia 55.4
Hypertension 66.5
Prior myocardial infarction 27.6
Creatinine clearance 60 ml/min 17.5
Prior CABG surgery 14.4
Medical therapy at presentation (%)
Aspirin 73.0
Beta-blockers 52.6
Statins 46.4
Prior antithrombin use 58.2
ACE inhibitors/ARBs 42.3
Thienopyridines 64.5
Elevation of cardiac biomarkers (%) 64.1
Elevation of troponin (%) 62.5
ST-segment deviation 1 mm (%) 39.3
TIMI risk score
0–2 15.7
3–4 54.0
5–7 30.2ACE  angiotensin-converting enzyme; ARB  angiotensin-receptor blocker; CA
percutaneous coronary intervention; TIMI Thrombolysis In Myocardial Infarctio4 h after clinical presentation. In contrast, patients who
nderwent PCI24 h after clinical presentation had higher
ates of death, MI, composite ischemia, and net adverse
linical events at 30 days in comparison with those who
nderwent earlier PCI (Fig. 1, Table 3). The increase in
ortality and combined death or MI among patients who
nderwent PCI 24 h after clinical presentation persisted
t 1-year follow-up (Fig. 2).
The rate of non-CABG–related major bleeding was
owest among patients who underwent PCI between 8 and
4 h after clinical presentation, with no significant differ-
nce present between patients who underwent PCI 8 h
nd those who underwent PCI 24 h after hospital admis-
ion. There also was no relation between PCI timing and
nal TIMI flow grade achieved with PCI. However, pa-
ients who underwent PCI 24 h after clinical presentation
ad the lowest incidence of early and late unplanned
evascularization (Table 3). This lower incidence was
resent even though both the prevalence of multivessel
isease and number of vessels treated with PCI were similar
cross the 3 PCI timing groups.
mpact of randomization. Within each of the 3 PCI
iming groups, there were no significant differences in
me to PCI
Time to PCI
8–24 h >24 h
p Value
(3 Groups)
62 (21–92) 63 (30–95) 0.0001
72.8 73.0 0.83
64.1 48.2 0.0001
85 (75–97) 83 (73–95) 0.001
27.2 29.2 0.04
7.6 8.6 0.30
32.3 30.1 0.14
56.8 55.8 0.59
64.8 65.3 0.45
31.1 31.8 0.004
17.3 20.2 0.01
18.0 19.3 0.0001
68.6 67.0 0.0001
48.5 47.3 0.0005
47.6 47.4 0.64
69.3 67.5 0.0001
39.3 41.7 0.07
64.9 68.1 0.0001
64.6 66.2 0.29
64.2 66.3 0.03
32.1 36.6 0.0001
15.6 16.7 0.51
55.4 50.9 0.006
29.1 32.4 0.04CIto TiBG  coronary artery bypass grafting; IQR  interquartile range; PCI 
n.
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April 6, 2010:1416–24 Risk of PCI Delay in ACS0-day mortality, MI, unplanned revascularization, or com-
osite ischemia among the 3 randomized antithrombotic
egimens (p  0.05 for all comparisons). The rate of
on-CABG major bleeding, however, was lower among
atients assigned to bivalirudin alone compared with a
lycoprotein IIb/IIIa inhibitor-based regimen, regardless of
he time delay to PCI (Fig. 3).
ngiographic Characteristics androcedural Results According to Time to PCITable 2 Angiograph c Characteristics andProcedural Results According to Time to PCI
Time to PCI
<8 h 8–24 h >24 h
p Value
(3 Groups)
Culprit lesion (%)
Left anterior descending 44.8 41.4 43.1 0.06
Left circumflex 34.6 33.7 36.2 0.14
Right coronary artery 34.4 39.7 35.8 0.0003
Left main 1.0 1.6 2.0 0.01
Baseline TIMI flow grade (%)
0/1 30.3 22.2 21.5 0.0001
2 21.9 19.2 16.5 0.0001
3 51.5 63.0 66.8 0.0001
Antithrombin treatment
Unfractionated heparin 19.4 17.4 12.3 0.0001
Low-molecular weight heparin 13.1 16.0 20.3 0.0001
Bivalirudin 67.5 66.6 67.4 0.78
Glycoprotein IIb/IIIa receptor
inhibitor usage (%)
Upstream 35.0 34.0 31.7 0.03
At time of PCI 31.1 33.1 33.9 0.11
Stent implanted (%) 91.8 92.2 91.8 0.82
Drug-eluting stent 54.7 65.0 58.2 0.0001
Final TIMI flow grade (%)
0/1 2.8 2.4 2.7 0.67
2 2.9 2.2 2.5 0.37
3 95.3 96.5 96.0 0.10
CI  percutaneous coronary intervention; TIMI  Thrombolysis In Myocardial Infarction.
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Figure 1 Timing of PCI After Clinical Presentation
and 30-Day Outcomes
The end point of composite ischemia consists of death from any cause,
myocardial infarction (MI), or unplanned revascularization for ischemia. PCI 
percutaneous coronary intervention.wIMI risk score, PCI timing, and outcome. Delay to PCI
24 h after clinical presentation was associated with significant
ncreases in the rates of 30-day death and death or MI among
oth intermediate and high-risk patients (Fig. 4). In compar-
son with patients who had earlier PCI, high-risk patients
TIMI score  5 to 7) who had PCI delay 24 h also
emonstrated an approximately 2-fold increase in 30-day
ortality. The relation between PCI delay 24 h and risk
f death at 1-year follow-up persisted irrespective of the
aseline TIMI risk score, although the greatest difference in
eath was evident in the higher-risk patients (Fig. 5).
After multivariable adjustment for differences in baseline
haracteristics, a delay to PCI 24 h after clinical presen-
ation was a strong independent predictor of both death and
he combined end point of death or MI at 30 days and 1
ear (Tables 4 and 5).
iscussion
he principal findings of this investigation are: 1) delay to
CI 24 h after clinical presentation in patients with
STE-ACS is a strong, independent predictor of increased
0-day and 1-year mortality and combined death or MI;
) the hazard of PCI delay is greatest in the highest-risk
atients and is independent of antithrombin randomization;
nd 3) the benefits of bivalirudin monotherapy in reducing
emorrhagic complications while affording similar suppres-
ion of ischemic complications compared with a glyco-
rotein IIb/IIIa inhibitor based-regimen is independent of
ime from presentation to PCI.
Although clinical trials have established the benefits of an
arly invasive strategy for the majority of patients presenting
ith NSTE-ACS, the appropriate timing of angiography
nd revascularization has not been resolved. In prior ACS
tudies, the timing of angiography among patients managed
nadjusted 30-Day and 1-Yearvent Rates Accordi g to Time to PCITable 3 Unadjusted 30-Day and 1-YearEvent Rates According to Time to PCI
Time to PCI
<8 h 8–24 h >24 h
p Value
(3 Groups)
30-day (%)
Death 0.8 0.5 1.7 0.0001
Myocardial infarction 4.9 5.6 8.0 0.0001
Death or myocardial infarction 5.6 6.0 9.0 0.0001
Unplanned revascularization 4.2 3.4 2.8 0.02
Composite ischemia 7.9 7.9 10.4 0.001
Non-CABG major bleeding 6.2 4.8 6.8 0.005
Net clinical outcome 12.7 11.6 15.5 0.0001
1-year (%)
Death 2.9 2.2 4.3 0.0001
Myocardial infarction 7.8 7.7 10.7 0.0001
Death or myocardial infarction 10.1 9.3 13.7 0.0001
Unplanned revascularization 14.6 11.2 10.5 0.0001
Composite ischemia 19.5 16.8 20.3 0.002
ABG  coronary artery bypass grafting; PCI  percutaneous coronary intervention.ith an invasive strategy has varied considerably, ranging
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Risk of PCI Delay in ACS April 6, 2010:1416–24rom 1 to 4 days after clinical presentation (1–5). One small
andomized study has been published in which the optimal
iming of PCI in patients with NSTE-ACS has been
xamined, the ISAR-COOL (Intracoronary Stenting With
ntithrombotic Regimen Cooling-Off) trial. In this study
here was a significantly lower risk of death or MI in
atients with NSTE-ACS who underwent angiography 6
after clinical presentation (median time, 2.4 h) in com-
arison with those randomized to angiography after 3 to 5
ays of antithrombotic therapy (5.9% vs. 11.6%, p  0.04)
13). In a second, larger randomized trial of 3,031 patients
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Figure 2
Occurrence of Death at
1-Year Follow-Up According to
Timing of PCI After Clinical Presentation
Increasing delay in percutaneous coronary intervention (PCI) after clinical pre-
sentation was significantly associated with greater mortality (A) and combined
death or myocardial infarction (MI) (B) at 1-year follow-up (p  0.0001,
log-rank).ith NSTE-ACS, the TIMACS (Timing of Interventionn Acute Coronary Syndromes) trial, early angiography
median time, 14 h) did not lead to better outcomes except
n patients who were at high risk (14). Other observational
tudies describing the impact of the timing of angiography
nd revascularization on the outcomes of patients with ACS
ave been inconsistent, with clinical benefit from expedi-
ious angiography being evident in some but not all studies
8–12).
In the present large-scale, multicenter, randomized trial,
here was a strong, independent association of PCI delay
24 h after clinical presentation with NSTE-ACS and
ubsequent mortality and adverse clinical outcomes. An
ncrease in mortality was observed early with PCI delay and
ersisted throughout the 1-year follow-up period and was
articularly evident among high-risk patients. There also
as an increased risk of MI and composite ischemia among
atients with PCI delay 24 h. Of note, the 30-day rate of
eath or MI for patients undergoing PCI 8 h after
ospital admission in the present investigation (5.6%) was
imilar to that observed among patients who underwent
arly angiography in the ISAR-COOL trial (5.9%) (13).
he present findings also are consistent with those recently
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April 6, 2010:1416–24 Risk of PCI Delay in ACSeported in a post hoc analysis from the SYNERGY
Superior Yield of the New Strategy of Enoxaparin, Revas-
ularization, and Glycoprotein IIb/IIIa inhibitors) trial,
hich reported less death and MI for patients undergoing
ngiography within 6 h after clinical presentation (12).
In the ACUITY trial, timing of angiography and PCI
as left to the discretion of the local investigator. Prior
tudies have identified clinical variables predictive of angio-
raphic delay in NSTE-ACS patients (12). To help address
otential selection bias, we examined the hazard of PCI
elay according to patient risk at presentation (i.e., TIMI
core) and also after multivariable adjustment for differences
n baseline characteristics. In these analyses, there was an
ssociation between increased patient risk and the hazard of
CI delay. These findings are consistent with those of the
IMACS trial, which demonstrated less death, MI, and
troke for high-risk patients with NSTE-ACS who were
andomized to earlier angiography (14). Nonetheless, even
mong the low-risk patients (TIMI score  0 to 2), there
as a significantly higher 1-year mortality rate in our study
mong those who had PCI24 h after clinical presentation
han among patients who had earlier PCI. Furthermore,
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Figure 4 30-Day Outcomes by Patient Risk and Timing of PCI
Risk for each patient was classified according to Thrombolysis In Myocardial Infarc
versus PCI  8 to 24 h; **p  0.05 versus both PCI  8 to 24 h and PCI 8 h;ultivariable analyses confirmed the independent impact of tCI delay 24 h in the overall study population for both
arly and late adverse events.
The present investigation, the largest to date examining
he impact of treatment-related delays on patient outcomes,
n which antithrombotic therapy was systematically admin-
stered to all patients before an early invasive management
trategy, reconciles and extends the conflicting findings
rom previous reports examining the implications of treat-
ent delays in ACS patients. In the PURSUIT (Platelet
lycoprotein IIb/IIIa in Unstable Angina: Receptor Sup-
ression Using Integrilin Therapy) trial, the lowest rates of
eath and MI occurred among those treated with eptifi-
atide and PCI within 24 h of clinical presentation (18). In
his study, however, no difference in death or MI according
o timing of PCI was noted for patients treated without a
lycoprotein IIb/IIIa receptor inhibitor (18). Benefits of
xpeditious angiography for patients with NSTE-ACS
ave been observed in other studies in which antithrom-
otic and antiplatelet therapy was administered early as
er current guideline recommendations (6,8,12) but not
n others in which these therapies were used less fre-
uently (10,11). Intense antiplatelet and antithrombotic
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Risk of PCI Delay in ACS April 6, 2010:1416–24STE-ACS undergoing very early PCI, in whom plate-
et activation is heightened, facilitating the safe perfor-
ance of early PCI (19).
Prolonged medical therapy might theoretically be bene-
cial in decreasing the angiographic thrombus burden in
atients with NSTE-ACS (20,21). In a pooled analysis of
ngiographic trials, the presence of thrombus was associated
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Figure 5 1-Year Mortality by Patient Risk and Timing of PCI
Risk for each patient was classified according to Thrombolysis In Myocardial
Infarction (TIMI) score (0 to 2  low, 3 to 4  intermediate, 5 to 7  high).
(A) Low-risk; (B) intermediate-risk; (C) high-risk. PCI  percutaneous coronary
intervention.ith a higher rate of abrupt closure, MI, and in-hospital Aepeat revascularization (22). Nevertheless, in the present
tudy, rates of death and MI were lowest among patients
ho had early PCI, without increased bleeding, although
he rates of unplanned revascularization were higher in this
roup. The explanation underlying the increased incidence
f both early and late unplanned repeat revascularization
mong the early PCI group, also noted from the PURSUIT
rial (8), is not known but might be due to more extensive
nd/or severe vascular disease in patients requiring earlier
ultivariable Predictors ofea h at 30 Days and 1 YearTable 4 Multiv riable Predictors ofDeath at 30 Days and 1 Year
Hazard Ratio 95% CI p Value
30-day death
Age 75 yrs 4.18 2.59–6.73 0.0001
Male sex 1.39 0.82–2.35 0.22
Anemia 1.94 1.18–3.19 0.009
Prior stroke or TIA 1.71 1.07–2.73 0.02
Elevation of cardiac biomarkers 4.25 2.14–8.42 0.0001
ST-segment deviation 1 mm 1.72 1.08–2.73 0.02
Known CAD 1.70 1.04–2.77 0.04
PCI delay 24 h 2.14 1.35–3.39 0.001
1-yr death
Age 75 yrs 2.66 1.94–3.65 0.0001
Male sex 1.26 0.93–1.70 0.13
Anemia 1.54 1.14–2.07 0.005
Creatinine clearance 60 ml/min 1.63 1.18–2.25 0.003
Prior stroke or TIA 1.43 1.06–1.91 0.02
Elevation of cardiac biomarkers 2.07 1.51–2.84 0.0001
ST-segment deviation 1 mm 1.51 1.15–1.97 0.003
Known CAD 1.90 1.41–2.56 0.0001
Diabetes mellitus 1.82 1.41–2.34 0.0001
PCI delay 24 h 1.57 1.20–2.04 0.0008
AD  coronary artery disease; CI  confidence interval; PCI  percutaneous coronary interven-
ion; TIA  transient ischemic attack.
ultivariable Predictors of the Combined End Pointf Death or Myocardial Infarction at 30 Daysnd 1 Ye r
Table 5
ultivari ble Predictors of the Combined End Point
of Death or Myocardial Infarction at 30 Days
and 1 Year
Hazard Ratio 95% CI p Value
30-day death or myocardial infarction
Age 75 yrs 1.18 0.93–1.50 0.18
Creatinine clearance 60 ml/min 1.36 1.08–1.71 0.01
Elevation of cardiac biomarkers 1.40 1.14–1.71 0.001
ST-segment deviation 1 mm 1.22 1.02–1.46 0.03
Known CAD 1.47 1.21–1.79 0.0001
PCI delay 24 h 1.51 1.27–1.80 0.0001
1-yr death or myocardial infarction
Age 75 yrs 1.14 0.95–1.38 0.16
Anemia 1.20 1.01–1.43 0.04
Creatinine clearance 60 ml/min 1.53 1.27–1.83 0.0001
Prior stroke or TIA 1.28 1.06–1.53 0.009
Elevation of cardiac biomarkers 1.42 1.21–1.66 0.0001
ST-segment deviation 1 mm 1.17 1.01–1.35 0.04
Known CAD 1.79 1.51–2.12 0.0001
Diabetes mellitus 1.18 1.01–1.37 0.03
PCI delay 24 h 1.36 1.18–1.56 0.0001bbreviations as in Table 4.
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April 6, 2010:1416–24 Risk of PCI Delay in ACSntervention or greater systemic inflammation in patients with
STE-ACS requiring early PCI (8,23,24). Nonetheless, these
ata in aggregate support expeditious angiography and revas-
ularization when appropriate in moderate- and high-risk
atients with NSTE-ACS after initial treatment with anti-
latelet and antithrombotic therapy.
Several inherent limitations of the present analysis should
e acknowledged, including selection and survivor biases.
recise reasons for PCI delay were not prospectively col-
ected, and there were significant baseline differences be-
ween groups. Although multivariable adjustment was used
o correct for measured differences between the groups, we
annot exclude the presence of unmeasured confounders.
or example, it cannot be known with certainty whether
atients who underwent late PCI did so because they were
oo ill for earlier angiography or were more stable, thus not
equiring very early angiography. It is important to note that
his study is a post hoc analysis, and our findings should
herefore be interpreted as hypothesis-generating. Of note,
n analyses that examined outcome according weekend or
eekday presentation, there were no differences in mortal-
ty, ischemic events, or bleeding. Bleeding rates were lower
n the bivalirudin monotherapy arms for each of the PCI
iming groups. Mortality did not differ according to the
andomized antithrombotic regimen within each PCI tim-
ng group, but the 30-day death rates were low (1%).
Despite these caveats, the present findings—taken in con-
ert with those from earlier observational studies, the random-
zed ISAR-COOL trial, and the randomized TIMACS
rial—suggest that patients with moderate- and high-risk
STE-ACS in whom an early invasive strategy is planned
enefit from urgent triage (within 8 h) to angiography and
evascularization when appropriate, particularly for those
atients in whom high-risk features are present. Adopting a
olicy of expedited angiography for all patients with NSTE-
CS would require additional hospital staffing and poten-
ially greater resource use and costs due to the large number
f NSTE-ACS patients admitted to hospitals each year
1.5 million in the U.S.) (25). However, this economic
urden might be counterbalanced by significant reductions
n mortality, ischemic outcomes, and shorter hospital stays.
he present study thus warrants further large-scale, ran-
omized investigations of expedited versus delayed angiog-
aphy in patients with NSTE-ACS in whom an invasive
anagement strategy is planned, with co-primary end
oints of clinical efficacy and cost-effectiveness.
eprint requests and correspondence: Dr. Gregg W. Stone, The
ardiovascular Research Foundation, 111 East 59th Street, 11th
loor, New York, New York 10022. E-mail: gstone@crf.org.
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